eDiets.com(R) Announces Q3 2008 Results(plans and may also be offered for free; ...),Health

Date:11/13/2008

plans and may also be offered for free; volatility in the advertising markets; any delay, disruption, or suspension of our supply of prepared meals from our vendor; changes in consumer preferences and discretionary spending; product liability and other risks from the sale of ingested products; regulatory actions affecting our marketing activities; and the outcome of litigation pending against us. For additional information regarding these and other risks and uncertainties associated with eDiets.com's business, reference is made to our Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed from time to time with the Securities and Exchange Commission. All forward-looking statements are current only as of the date on which such statements are made. We do not undertake any obligation to publicly update any forward- looking statements.

--Financial Tables Follow --

eDiets.com, Inc.

Summary of Consolidated Financial Information

(Unaudited)

(In thousands, except per share amounts)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues:

Digital plans $2,079 $4,369 $7,815 $15,625

Meal delivery 1,417 1,035 8,239 2,427

Other 1,257 1,431 3,914 4,777

Total revenues 4,753 6,835 19,968 22,829

Cost and expenses:

Cost of revenue

Digital plans 640 787 1,838 2,443

Meal delivery 1,407 944 8,530 2,233

Other 108
'/>"/>

SOURCE eDiets.com, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. eDiets.com(R) to Report Third Quarter 2008 Results on Thursday, November 13, 2008
2. eDiets.com(R) Announces Q2 2008 Results
3. eDiets.com(R) Appoints New Chief Information Officer Laura Klein
4. eDiets.com(R) Announces Q1 2008 Results
5. eDiets.com(R) to Report First Quarter 2008 Results on Tuesday, May 13, 2008
6. eDiets.com(R) Announces Q4 and Year End 2007 Results
7. eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call
8. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
9. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
10. Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer
11. In a Down Economy, Womens Health Company Announces Growth